RxDoctor Payments Data

Adam Fish, DO

Anesthesiology · San Antonio, TXNPI 1689105678

Payments from drug & device makers

$7,704in general payments, 2019–2025

Across 155 payments — averaging $49.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$2K
  • Relievant Medsystems, Inc.$1K
  • Abbott$1K
  • AbbVie$271
  • Nevro Corp.$257
  • plus $1K from 16 others

What the payments were for

  • Grants$1,75423%
  • Travel & lodging$1,91625%
  • Food & beverage$4,00152%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,704 in reported general payments places this provider in the 95th percentile of 3,899 anesthesiology providers in Texas.

See all anesthesiology providers in Texas

Medicare billing

Part B allowed, 2024
$365,675
Medicare patients
457
Services billed
7,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl52$45,382
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen960$41,329
Xtampza ErOxycodone Myristate33$20,236
Buprenorphine48$12,935
Lidocaine65$6,956
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen149$5,419
Naloxone Hcl82$4,984
OxycontinOxycodone Hcl14$4,585
Gabapentin293$3,757
Oxycodone Hcl155$3,507
Morphine Sulfate ErMorphine Sulfate106$3,232
Pregabalin100$2,531
Cyclobenzaprine Hcl79$1,650
Ondansetron Hcl18$1,554
Tizanidine Hcl125$1,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$145$65,61885 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$35$13,44165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,899 anesthesiology providers in Texas.

Other anesthesiology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →